Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy

Oncogene

Volumn 27, Issue 30, 2008, Pages 4233-4241

  Eelen, G ^a   Vanden Bempt, I ^b   Verlinden, L ^a   Drijkoningen, M ^b   Smeets, A ^b   Neven, P ^b   Christiaens, M R ^b   Marchal, K ^a   Bouillon, R ^a   Verstuyf, A ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; Brip1; E2F; HER 2; High grade; Vitamin D

Indexed keywords

BRCA1 PROTEIN; CALCITRIOL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; ARTICLE; BACH1 GENE; BREAST CANCER; BRIP1 GENE; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; FANCJ GENE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BINDING SITES; BREAST NEOPLASMS; CARCINOMA; CONSERVED SEQUENCE; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; RNA HELICASES; SEQUENCE HOMOLOGY, NUCLEIC ACID; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 47049108873     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.51     Document Type: Article

References (32)

1. Bracken AP, Ciro M, Cocito A, Helin K. (2004). E2F target genes: unraveling the biology. Trends Biochem Sci 29: 409-417.
2. Bridge WL, Vandenberg CJ, Franklin RJ, Hiom K. (2005). The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Nat Genet 37: 953-957.
3. Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S et al. (2004). The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci USA 101: 2357-2362.
4. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S et al. (2001). BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105: 149-160.
5. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL et al. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541.
6. D'Andrea AD, Grompe M. (2003). The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3: 23-34.
7. Eelen G, Gysemans C, Verlinden L, Vanoirbeek E, De Clercq P, Van Haver D et al. (2007). Mechanism and potential of the growth-inhibitory actions of vitamin D and Analogs. Curr Med Chem 14: 1893-1910.
8. 3-treated MC3T3-E1 cells. J Steroid Biochem Mol Biol 89-90: 405-407.
9. Eelen G, Verlinden L, Van Camp M, van Hummelen P, Marchal K, de Moor B et al. (2004b). The effects of 1alpha, 25-dihydroxyvitamin D3 on the expression of DNA replication genes. J Bone Miner Res 19: 133-146.
10. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R et al. (2006). Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6: 96.
11. 2/M-specific transcription. Genes Dev 18: 2941-2951.
12. Ishida R, Buchwald M. (1982). Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents. Cancer Res 42: 4000-4006.
13. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW et al. (2005). The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37: 934-935.
14. Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P et al. (2005). The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37: 931-933.
15. Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S et al. (2005). BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8: 255-265.
16. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D et al. (2004). Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13: 1303-1313.
17. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA et al. (2000). Molecular portraits of human breast tumours. Nature 406: 747-752.
18. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. (2002). Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31: 33-36.
19. Poll EH, Arwert F, Joenje H, Eriksson AW. (1982). Cytogenetic toxicity of antitumor platinum compounds in Fanconi's anemia. Hum Genet 61: 228-230.
20. Raemaekers T, Ribbeck K, Beaudouin J, Annaert W, Van Camp M, Stockmans I et al. (2003). NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization. J Cell Biol 162: 1017-1029.
21. Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK. (2002). Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 198: 157-162.
22. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R et al. (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38: 1239-1241.
23. Sinclair CS, Rowley M, Naderi A, Couch FJ. (2003). The 17q23 amplicon and breast cancer. Breast Cancer Res Treat 78: 313-322.
24. Sorlie T. (2004). Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40: 2667-2675.
25. 3. J Biol Chem 280: 37319-37330.
26. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K et al. (2007). The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res 67: 6574-6581.
27. Whitfield ML, George LK, Grant GD, Perou CM. (2006). Common markers of proliferation. Nat Rev Cancer 6: 99-106.
28. Yan Z, DeGregori J, Shohet R, Leone G, Stillman B, Nevins JR et al. (1998). Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci USA 95: 3603-3608.
29. Yang L, Han Y, Saurez SF, Minden MD. (2007). A tumor suppressor and oncogene: the WT1 story. Leukemia 21: 868-876.
30. Yu X, Chini CC, He M, Mer G, Chen J. (2003). The BRCT domain is a phospho-protein binding domain. Science 302: 639-642.
31. Zacharatos P, Kotsinas A, Evangelou K, Karakaidos P, Vassiliou LV, Rezaei N et al. (2004). Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol 203: 744-753.
32. Zhang SY, Liu SC, Al Saleem LF, Holloran D, Babb J, Guo X et al. (2000). E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 9: 395-401.